Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual park cycling could slow muscle decline in children

NCT ID NCT07580365

Symptom relief Sponsor: Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether cycling while using a virtual park app can slow the loss of motor function in children and teens with neuromuscular diseases like muscular dystrophy. Twenty-two participants will first receive standard care for 3 months, then use the virtual park bike 3 times a week for another 3 months. The goal is to see if the dual-task training improves movement, thinking, and engagement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dual-task cycling with VirtualPark software
What this could lead to
If it works, this could provide a fun, engaging way to help children with neuromuscular diseases maintain their motor function longer.
What could go wrong
This is a very small early trial with only 22 participants, so results may not apply widely. The intervention is non-invasive but may not slow decline significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 22 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease; * age between 6 years and 17 years and 11 months (inclusive); * height compatible with the use of the Thera-Trainer (minimum 120 cm); * performance Upper Limb Module 2.0 assessment: Entry level \>= 2 Exclusion Criteria: * other concomitant genetic diseases; * presence of visual impairments that prevent access to the experimental virtual reality protocol; * concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training; * severe osteoporosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital myopathies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital myopathy muscular dystrophy neuromuscular disease neuromuscular disease caused by qualitative or quantitative defects of dystrophin Thomsen and Becker disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital myopathies Dystrophinopathy Muscular dystrophies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Don Gnocchi - Centro "S. Maria al Mare"

    SUSPENDED

    Salerno, SA, 84131, Italy

  • IRCCS E. Medea - La Nostra Famiglia

    RECRUITING

    Bosisio Parini, LC, 23849, Italy

  • IRCCS Fondazione Mondino

    RECRUITING

    Pavia, PV, 27100, Italy

  • IRCCS Fondazione Stella Maris

    RECRUITING

    Pisa, PI, 56128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.